Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2025Frontiers in Cardiovascular MedicineOpen Access

Emerging therapy targets to modulate microbiome-mediated effects evident in cardiovascular disease

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDorothea Katharina HoffelnerTHTim Hendrikx

Discussion

Loading...

Member takes

Overview

This review demonstrates the microbiome's role in cardiovascular disease, highlighting therapeutic targets including prebiotics and probiotics.

Key Points

  • Microbial dysbiosis is linked to increased cardiovascular disease risk and metabolic disorders.
  • Metabolites influenced by the microbiome, like short-chain fatty acids, affect vascular health.
  • The gut-heart axis involves complex interactions between microbial communities and diet.
  • Targeting the microbiome with prebiotics and probiotics can help reduce residual cardiovascular disease risk.

Cite This Study

Hoffelner et al. (2025) studied this question.

synapsesocial.com/papers/689a02c3e6551bb0af8ccb98https://doi.org/10.3389/fcvm.2025.1631841
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gut Microbiota: Cardiovascular Disease Prevention and Targeted Therapies2026
  2. 2The gut-heart connection: how the microbiome influences cardiovascular health2025
  3. 3The gut-heart axis: Exploring the role of the gut microbiome in cardiovascular health – A focused systematic review2025 · 3 citations
  4. 4Gut Microbiota and Its Implications for Cardiovascular Diseases – a Review2024 · 3 citations
  5. 5The Gut–Heart Axis: A Comprehensive Review of Microbiota’s Role in Cardiovascular Health and Disease and Emerging Therapeutic Strategies2026 · 10 citations